PMID- 32301018
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20200701
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1244
DP  - 2020
TI  - Skin Reactions to Immune Checkpoint Inhibitors.
PG  - 235-246
LID - 10.1007/978-3-030-41008-7_11 [doi]
AB  - Due to the novelty of immune checkpoint inhibitors, their cutaneous adverse 
      events (AEs) have only been recently characterized. This, along with the 
      substantial rate of cutaneous reactions, has left many clinicians without 
      sufficient familiarity to diagnose and treat cutaneous AEs. Pruritus and rash are 
      among the top five immune-related AEs reported in clinical trials for this class 
      of therapy. Incidence varies between 35 and 50% for cutaneous AEs among the eight 
      FDA-approved drugs. Although only 2% are reported as grade 3 or 4 events, the 
      impact on quality of life can be significant for these patients and is best 
      described and most severe in ipilimumab trials. Of ipilimumab patients, 43.5% 
      have a cutaneous AE and, at our institution, 20% of them had a dose interruption 
      as a result. This means potentially 9% of patients have dose interruption of 
      ipilimumab because of their cutaneous AEs. In the following chapter, we review 
      the categories of these drugs, common cutaneous effects, their grading, and 
      management options.
FAU - Patel, Anisha B
AU  - Patel AB
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA. APatel11@mdanderson.org.
FAU - Pacha, Omar
AU  - Pacha O
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*adverse effects
MH  - Exanthema/*chemically induced/diagnosis/therapy
MH  - Humans
MH  - Immunotherapy/*adverse effects
MH  - Ipilimumab/*adverse effects
MH  - Neoplasms/immunology/*therapy
MH  - Pruritus/*chemically induced/diagnosis/therapy
MH  - Quality of Life
OTO - NOTNLM
OT  - Anti-CTLA-4
OT  - Dermatitis
OT  - Immune checkpoint inhibitors
OT  - Immunotherapy
OT  - Ipilimumab
OT  - Nivolumab Anti-PD-1
OT  - Pruritus
OT  - Rash
EDAT- 2020/04/18 06:00
MHDA- 2020/07/02 06:00
CRDT- 2020/04/18 06:00
PHST- 2020/04/18 06:00 [entrez]
PHST- 2020/04/18 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
AID - 10.1007/978-3-030-41008-7_11 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2020;1244:235-246. doi: 10.1007/978-3-030-41008-7_11.